Floatz Rating
B59/100
Confidence
Indicative
Sponsor
Vall d'Hebron Institute of Oncology
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
59High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07593820CT.gov A Phase I Interventional Open-label, Non-randomized Dose-escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Anti-tumor Activity of Autologous p95HER2.CAR-TECH2Me T Cells in Patients With Selected Advanced Cancers. | — | Recruiting | — | — | — |
NCT07510802CT.gov Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC | — | Recruiting | — | — | — |
NCT07486089CT.gov Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC) | — | Recruiting | — | — | — |
NCT07410494CT.gov Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT04119024CT.gov Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT06341647CT.gov Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201 | — | Withdrawn | — | — | — |
NCT06532812CT.gov TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer | — | Recruiting | — | — | — |
NCT06347068CT.gov Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells | — | Recruiting | — | — | — |
NCT06253520CT.gov Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer | — | Active Not Recruiting | — | — | — |
NCT04102436CT.gov Non-Viral TCR Gene Therapy | — | Withdrawn | — | — | — |
Show 28 more trialsShow fewer
NCT06010862CT.gov Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors | — | Recruiting | — | — | — |
NCT05678205CT.gov A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors | — | Withdrawn | — | — | — |
NCT05877599CT.gov A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation | — | Recruiting | — | — | — |
NCT05576077CT.gov A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT05483491CT.gov KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer | — | Recruiting | — | — | — |
NCT05395052CT.gov FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors | — | Terminated | — | — | — |
NCT04639245CT.gov Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer | — | Terminated | — | — | — |
NCT04511871CT.gov A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT04348643CT.gov Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer | — | Unknown | — | — | — |
NCT03412877CT.gov Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer | — | Recruiting | — | — | — |
NCT02830724CT.gov Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers | — | Recruiting | — | — | — |
NCT02457650CT.gov T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies | — | Unknown | — | — | — |
NCT02153905CT.gov T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive | — | Terminated | — | — | — |
NCT02111850CT.gov T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive | — | Completed | — | — | — |
NCT01967823CT.gov T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer | — | Completed | — | — | — |
NCT01105650CT.gov Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer | — | Completed | — | — | — |
NCT01212887CT.gov Treated Blood Cells, Cyclophosphamide, Fludarabine Phosphate, and Aldesleukin in Treating Patients With Cancer | — | Terminated | — | — | — |
NCT00020722CT.gov Chemotherapy Followed by Peripheral Stem Cell Transplantation Plus Biological Therapy in Treating Women With Stage IV Breast Cancer | — | Terminated | — | — | — |
NCT00376805CT.gov Allogeneic Natural Killer (NK) Cells in Patients With Advanced Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT00074269CT.gov Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Breast Cancer | — | Terminated | — | — | — |
NCT00027807CT.gov Biological Therapy in Treating Women With Stage IV Breast Cancer | — | Completed | — | — | — |
NCT00020176CT.gov Allogeneic Peripheral Stem Cell Transplantation in Treating Patients With Stage IV Breast Cancer | — | Completed | — | — | — |
NCT00006261CT.gov Allogeneic Transplantation Using Mini-Conditioning for Treatment of Stage IV Breast Cancer | — | Withdrawn | — | — | — |
NCT00022230CT.gov Combination Chemotherapy Plus Biological Therapy in Treating Patients With Stage II or Stage III Breast Cancer | — | Withdrawn | — | — | — |
NCT00003972CT.gov Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage II or Stage IIIA Breast Cancer | — | Completed | — | — | — |
NCT00003199CT.gov Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer | — | Completed | — | — | — |
NCT00019084CT.gov Vaccine Therapy and Biological Therapy in Treating Patients With Advanced Cancer | — | Completed | — | — | — |
NCT00060255CT.gov High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Breast Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Fludarabine (this asset) | Vall d'Hebron Institute of Oncology | P3 | B · 59 |
| Darolutamide | Vandana Abramson | P2 | BBB |
| Pertuzumab | SWOG Cancer Research Network | P4 | BB |
| Palbociclib | Hoffmann-La Roche | P4 | BB |
| Trastuzumab Duocarmazine | Byondis B.V. | P3 | BB |
| Goserelin | TerSera Therapeutics LLC | P4 | BB |
| Ribociclib | National Cancer Institute (NCI) | P4 | BB |
| Oxaliplatin | Beijing Biostar Pharmaceuticals Co., Ltd. | P4 | BB |
| Eribulin Monomethanesulfonate | Henan Cancer Hospital | P4 | BB |
+42 more in the Breast Cancer cohort
Other indications for Fludarabine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult T-Cell Leukemia/Lymphoma | — | P2 | BBB · 76 |
| Acute Myeloid Leukemia With Abnormal Bone Marrow Eosinophils Inv(16)(P13q22) Or T(16;16)(P13;Q22) | — | P2 | BBB · 76 |
| Fanconi Anemia | — | P2/3 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Fludarabine in Breast Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 11, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/fludarabine-breast-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →